glp 1 diabete GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1-based therapies for type 2

Medical documentation: Prescription records for all medications Doctors notes about medication changes Records of reported side effects Diagnostic testing and when it was performed How this affects your case: If symptoms began with the first drug: Clear temporal relationship Strong causation argument May have claims against that manufacturer If symptoms worsened with each subsequent drug: Cumulative damage theory May have claims against multiple manufacturers Important to show progression If symptoms appeared only after starting the second or third drug: Still valid claim May need to address why earlier drug was tolerated Focus on the drug most directly linked to injury Causation analysis: Your medical experts will examine: Which drug you were taking when symptoms began Whether cumulative exposure contributed Whether one drugs effects sensitized you to another The biological plausibility of the timeline Multiple defendants: If you took medications from both Novo Nordisk and Eli Lilly, you may have claims against both companies

PMID 17498508

8 Walker, E

Understanding why GLP-1 therapy may not be effective for you is the first step towards finding the right solution, whether that involves optimising your current treatment, switching medications, or exploring alternative approaches tailored to your individual circumstances

Interest in using weight-loss medications Among participants who had not used a GLP-1, GLP-1/GIP, or other medication for weight loss in the past year (96.0% [95.596.6%] of the sample), 6.5% [5.77.3%] said they would be likely to consider using a weight-loss medication in the next year (2.5% [2.13.0%] very likely and 4.0% [3.44.6%] fairly likely